- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02253095
Combined Package of Interventions for Environmental Enteropathy
June 2, 2015 updated by: Washington University School of Medicine
Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children
Randomized, double-blind, placebo controlled trial of a combined intervention of zinc, albendazole, and multiple micronutrients in improving environmental enteropathy in Malawian children.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
253
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Machinga Distric
-
Limela, Machinga Distric, Malawi
- Limela Rural Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 2 years (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- children residing in catchment area of Limela, Machinga District, Malawi
- aged 12-35 months
- youngest eligible child in each household
Exclusion Criteria:
- severe acute malnutrition
- severe chronic illness
- children unable to drink 20 mL of dual sugar solution
- children in need of acute medical treatment for illness or injury at time of enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Multiple Intervention Arm
single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
|
|
PLACEBO_COMPARATOR: Placebo
three placebos
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dual Sugar Absorption Test
Time Frame: 12 weeks
|
lactulose-mannitol ratio in urine
|
12 weeks
|
Dual Sugar Absorption Test
Time Frame: 24 weeks
|
lactulose-mannitol ratio in urine
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lactulose Excretion
Time Frame: 12 weeks
|
percentage of ingested lactulose excreted in urine
|
12 weeks
|
Lactulose Excretion
Time Frame: 24 weeks
|
percentage of ingested lactulose excreted in urine
|
24 weeks
|
Mannitol Excretion
Time Frame: 12 weeks
|
percentage of ingested mannitol excreted in urine
|
12 weeks
|
Mannitol Excretion
Time Frame: 24 weeks
|
percentage of ingested mannitol excreted in urine
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Chrissie Thakwalakwa, PhD, University of Malawi
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (ACTUAL)
April 1, 2015
Study Completion (ACTUAL)
April 1, 2015
Study Registration Dates
First Submitted
September 26, 2014
First Submitted That Met QC Criteria
September 30, 2014
First Posted (ESTIMATE)
October 1, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
June 3, 2015
Last Update Submitted That Met QC Criteria
June 2, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Micronutrients
- Trace Elements
- Albendazole
Other Study ID Numbers
- EE-zinc-alb-micronut
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Environmental Enteropathy
-
Washington University School of MedicineCompleted
-
Tropical Gastroenterology & Nutrition Group (TROPGAN)Bill and Melinda Gates FoundationNot yet recruitingEnvironmental EnteropathyBangladesh, Pakistan, Senegal, Zambia
-
Washington University School of MedicineCompletedEnvironmental EnteropathyMalawi
-
Institut Pasteur de DakarBill and Melinda Gates Foundation; Aga Khan University; International Centre... and other collaboratorsNot yet recruitingEnvironmental Enteric Dysfunction | ProbioticSenegal
-
Children's Hospital Medical Center, CincinnatiUniversidade Federal do CearáCompletedDiarrhea | Malnutrition | Environmental EnteropathyBrazil
-
National Institute for Medical Research, TanzaniaLondon School of Hygiene and Tropical Medicine; University of Copenhagen; Queen...Active, not recruitingDiabetes | HIV | Environmental EnteropathyTanzania
-
Massachusetts General HospitalRecruitingInflammatory Bowel Diseases | Crohn Disease | Permeability; Increased | Inflammatory Disease | Environmental EnteropathyUnited States
-
Regeneron PharmaceuticalsActive, not recruitingCD55-deficient Protein-losing Enteropathy | CHAPLEUnited States, Thailand, Turkey
-
Regeneron PharmaceuticalsAvailableCD55-Deficient Protein-Losing Enteropathy
-
Seoul National University HospitalNot yet recruitingFontan Operation | Protein-Losing Enteropathy | Camostat Mesylate
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States